Phase II Study of a B7-1 Gene-Modified Autologous Tumor Cell Vaccine and Systemic IL-2

You may be eligible if

• DISEASE CHARACTERISTICS:
• Histologically confirmed stage IV renal cell carcinoma
• * Symptomatic primary tumor or resectable metastasis
• Measurable disease post resection
• No symptomatic brain metastases
• PATIENT CHARACTERISTICS:
• Age:
• 18 and over
• Performance status:
• Eastern Cooperative Oncology Group (ECOG) 0-1
• Life expectancy:
• Not specified
• Hematopoietic:
• WBC greater than 4,000/mm\^3
• Platelet count greater than 100,000/mm\^3
• Hemoglobin greater than 10 g/dL
• Hematocrit greater than 30%
• Hepatic:
• Bilirubin less than 2 times normal
• SGOT less than 3 times normal
• Renal:
• Creatinine less than 1.5 mg/dL OR
• Creatinine clearance greater than 60 mL/min
• Cardiovascular:
• No evidence of active myocardial ischemia, prior myocardial infarction, or arrhythmia
• Other:
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception
• No contraindications to surgical resection
• No history of immunodeficiency disease
• No known allergy to penicillin
• PRIOR CONCURRENT THERAPY:
• Biologic therapy:
• Prior interleukin-2, interferon alfa, or other biologic agent allowed
• Chemotherapy:
• Not specified
• Endocrine therapy:
• No concurrent corticosteroids (except for replacement doses for adrenal insufficiency)
• Radiotherapy:
• Not specified
• Surgery:
• See Disease Characteristics
• Other:
• No concurrent immunosuppressants